The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 31 results:
Author Title Type [ Year(Asc)]
Filters: Author is Fountzilas, G  [Clear All Filters]
2014
Konstantopoulou, I., Tsitlaidou M., Fostira F., Pertesi M., Stavropoulou A-V., Triantafyllidou O., et al. (2014).  High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.. Clin Genet. 85(1), 36-42.
Dermitzakis, E. V., Kimiskidis V. K., Eleftheraki A., Lazaridis G., Konstantis A., Basdanis G., et al. (2014).  The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.. Eur J Neurol. 21(12), 1471-7.
Pentheroudakis, G., Kotteas E. A., Kotoula V., Papadopoulou K., Charalambous E., Cervantes A., et al. (2014).  Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.. Clin Exp Metastasis. 31(7), 761-9.
Koutras, A. K., Kotoula V., Papadimitriou C., Dionysopoulos D., Zagouri F., Kalofonos H. P., et al. (2014).  Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.. Pharmacogenomics J. 14(3), 248-55.
2013
Dionysopoulos, D., Pavlakis K., Kotoula V., Fountzilas E., Markou K., Karasmanis I., et al. (2013).  Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma.. Strahlenther Onkol. 189(3), 202-14.
Bamias, A., Tzannis K., Beuselinck B., Oudard S., Escudier B., Diosynopoulos D., et al. (2013).  Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.. Br J Cancer. 109(2), 332-41.
Martin, V., Landi L., Molinari F., Fountzilas G., Geva R., Riva A., et al. (2013).  HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.. Br J Cancer. 108(3), 668-75.
Rampias, T., Pectasides E., Prasad M., Sasaki C., Gouveris P., Dimou A., et al. (2013).  Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.. Ann Oncol. 24(8), 2124-31.
Pliarchopoulou, K., Kalogeras K. T., Kronenwett R., Wirtz R. M., Eleftheraki A. G., Batistatou A., et al. (2013).  Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.. Cancer Chemother Pharmacol. 71(1), 245-55.
Bamias, A., Dafni U., Karadimou A., Timotheadou E., Aravantinos G., Psyrri A., et al. (2013).  Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).. Ann Oncol. 24(4), 1011-7.
2012
Fountzilas, E., Markou K., Vlachtsis K., Nikolaou A., Arapantoni-Dadioti P., Ntoula E., et al. (2012).  Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer.. Ann Oncol. 23(8), 2146-53.
Psyrri, A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Batistatou A., Bournakis E., et al. (2012).  Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.. Ann Oncol. 23(6), 1422-7.
Pentheroudakis, G., Nicolaou I., Kotoula V., Fountzilas E., Markou K., Eleftheraki A. G., et al. (2012).  Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx.. Oral Oncol. 48(8), 709-16.
Skarlos, P., Christodoulou C., Kalogeras K. T., Eleftheraki A. G., Bobos M., Batistatou A., et al. (2012).  Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.. Cancer Chemother Pharmacol. 69(2), 533-46.
Koutras, A. K., Antonacopoulou A. G., Eleftheraki A. G., Dimitrakopoulos F-I., Koumarianou A., Varthalitis I., et al. (2012).  Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.. Pharmacogenomics J. 12(6), 468-75.
2011
Razis, E., Bobos M., Kotoula V., Eleftheraki A. G., Kalofonos H. P., Pavlakis K., et al. (2011).  Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.. Breast Cancer Res Treat. 128(2), 447-56.
Kosmidis, P. A., Fountzilas G., Eleftheraki A. G., Kalofonos H. P., Pentheroudakis G., Skarlos D., et al. (2011).  Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).. Ann Oncol. 22(4), 827-34.
2010
Ihnen, M., Wirtz R. M., Kalogeras K. T., Milde-Langosch K., Schmidt M., Witzel I., et al. (2010).  Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.. Br J Cancer. 103(7), 1048-56.
Dafni, U., Grimani I., Xyrafas A., Eleftheraki A. G., & Fountzilas G. (2010).  Fifteen-year trends in metastatic breast cancer survival in Greece.. Breast Cancer Res Treat. 119(3), 621-31.
Bamias, A., Karina M., Papakostas P., Kostopoulos I., Bobos M., Vourli G., et al. (2010).  A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.. Cancer Chemother Pharmacol. 65(6), 1009-21.
Pentheroudakis, G., Kostadima L., Dova L., Georgiou I., Tzavaras T., Vartholomatos G., et al. (2010).  A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer.. Neoplasma. 57(1), 47-54.
2009
Pectasides, D., Papaxoinis G., Nikolaou M., Valavanis C., Aravantinos G., Fountzilas G., et al. (2009).  Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1.. Anticancer Res. 29(2), 737-44.
Armaou, S., Pertesi M., Fostira F., Thodi G., Athanasopoulos P. S., Kamakari S., et al. (2009).  Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.. Br J Cancer. 101(1), 32-7.
Maniadakis, N., Dafni U., Fragoulakis V., Grimani I., Galani E., Fragkoulidi A., et al. (2009).  Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.. Ann Oncol. 20(2), 278-85.
Christodoulou, C., Dafni U., Aravantinos G., Koutras A., Samantas E., Karina M., et al. (2009).  Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.. Anticancer Res. 29(2), 693-702.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.